These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 21533567

  • 1. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
    Bendel SD, Bona R, Baker WL.
    Adv Ther; 2011 Jun; 28(6):460-72. PubMed ID: 21533567
    [Abstract] [Full Text] [Related]

  • 2. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
    [Abstract] [Full Text] [Related]

  • 3. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C, Barrios V, Jimenez D.
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [Abstract] [Full Text] [Related]

  • 4. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L, Chen C, White J.
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [Abstract] [Full Text] [Related]

  • 5. Dabigatran: will it change clinical practice?
    Wartak SA, Bartholomew JR.
    Cleve Clin J Med; 2011 Oct; 78(10):657-64. PubMed ID: 21968472
    [Abstract] [Full Text] [Related]

  • 6. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Chevalier J, Giroud M, de Pouvourville G.
    Cerebrovasc Dis; 2013 Oct; 35(4):320-6. PubMed ID: 23615428
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.
    Mack DR, Kim JJ.
    Ann Pharmacother; 2012 Oct; 46(7-8):1105-10. PubMed ID: 22764329
    [Abstract] [Full Text] [Related]

  • 8. Evaluating and assessing dabigatran drug interactions.
    Nguyen T, Wong E.
    Consult Pharm; 2012 Jul; 27(7):509-12. PubMed ID: 22910132
    [Abstract] [Full Text] [Related]

  • 9. Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
    Hughes PJ, Freeman MK.
    Consult Pharm; 2012 Jun; 27(6):445-52. PubMed ID: 22698551
    [Abstract] [Full Text] [Related]

  • 10. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.
    J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
    [Abstract] [Full Text] [Related]

  • 11. Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation.
    Moore CH, Snashall J, Boniface K, Scott J.
    Am J Emerg Med; 2012 Nov; 30(9):2082.e1-2. PubMed ID: 22196949
    [Abstract] [Full Text] [Related]

  • 12. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.
    Circulation; 2012 Feb 07; 125(5):669-76. PubMed ID: 22215856
    [Abstract] [Full Text] [Related]

  • 13. Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
    Baruch L, Sherman O.
    Ann Pharmacother; 2011 Jul 07; 45(7-8):e40. PubMed ID: 21712509
    [Abstract] [Full Text] [Related]

  • 14. The pharmacology and therapeutic use of dabigatran etexilate.
    Sarah S.
    J Clin Pharmacol; 2013 Jan 07; 53(1):1-13. PubMed ID: 23400738
    [Abstract] [Full Text] [Related]

  • 15. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
    Augoustides JG.
    J Cardiothorac Vasc Anesth; 2011 Dec 07; 25(6):1208-12. PubMed ID: 21982327
    [Abstract] [Full Text] [Related]

  • 16. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP.
    Am J Cardiovasc Drugs; 2011 Dec 07; 11(1):57-72. PubMed ID: 21265583
    [Abstract] [Full Text] [Related]

  • 17. Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.
    Meyer Dos Santos S, Harder S.
    Drug Saf; 2014 May 07; 37(5):295-307. PubMed ID: 24683059
    [Abstract] [Full Text] [Related]

  • 18. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
    Atay JK, Fanikos J, Barnes GD, Ehle M, Coatney J, Piazza G, Froehlich JB, Goldhaber SZ.
    Am J Cardiol; 2013 Aug 01; 112(3):387-9. PubMed ID: 23647794
    [Abstract] [Full Text] [Related]

  • 19. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A, Bailey C, Abdelhafiz AH.
    Age Ageing; 2012 Sep 01; 41(5):681-4. PubMed ID: 22378612
    [Abstract] [Full Text] [Related]

  • 20. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
    Galanis T, Merli GJ.
    Hosp Pract (1995); 2013 Feb 01; 41(1):26-36. PubMed ID: 23466965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.